AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Summary
- BioNTech (NASDAQ:BNTX) and Viatris (NASDAQ:VTRS) reported strong quarterly results on Aug 9, 2021.
- BioNTech’s revenue rose to €5.3 billion in the June quarter, a 12,630% YoY growth.
- Viatris Inc.’s revenue in the second quarter grew by 68% year-over-year.
The stocks of BioNTech SE (NASDAQ:BNTX) and Viatris Inc. (NASDAQ:VTRS) jumped around 5% on Monday after reporting strong revenue growth in their second quarter ended June 2021.
BNTX stock was priced at US$410.60, up 5.55% at 8:20 am ET, and VTRS stock was trading at US$14.89, up 4.49% at 8:23 am ET in the pre-market session.
Also Read: Check out these 3 renewable energy stocks for a green future
BioNTech SE (NASDAQ:BNTX)
The German biotechnology company’s revenue was €5,308.5 million in the quarter ended June 30, compared to €41.7 million in the same period of 2020.
Its net income was €2,787.2 million or €10.77 per share diluted compared to a net loss of €88.3 million or €0.38 per share diluted in the year-ago period.
The cash and cash equivalent for the period increased to €914.1 million from €573.0 million in a year-ago period.
BioNTech and its covid vaccine partner Pfizer Inc. expect to have a manufacturing capacity of 3 billion doses of the BNT162b2 vaccine this year and reach 4 billion doses in 2022.
BioNTech has 15 product candidates in the pipeline.
Its market cap is US$94 billion, with a P/E ratio of 68.13.
Also Read: Eight popular Nasdaq technology stocks under US$50
Source: Pixabay
Also Read: Four real estate stocks to watch as housing market booms
Viatris Inc.
The company has reported revenue of US$4.58 billion for the June quarter of 2021 compared to US$2.73 billion in the year-ago period.
It booked a net loss of US$279.2 million or US$0.23 per share diluted compared to the net income of US$39.4 million or US$0.08 per share diluted for the same quarter in 2020. The free cash flow was US$470 million.
Its updated revenue guidance ranges from US$17.5 billion to US$17.9 billion from the previous US$17.2 billion to US$17.8 billion. Adjusted EBITDA is expected in the range of US$6.15 billion to US$6.45 billion from the earlier guidance of US$6.0 billion to US$6.4 billion.
Guidance for free cash flow is US$2.2 billion to US$2.4 billion from the earlier US$2.0 billion to US$2.3 billion. Viatris has 1,400 approved molecules in its portfolio in various therapeutic areas.
Also Read: Virgin Galactic (SPCE) & Astra Space (ASTR): 2 space stocks flying high
It has around 40,000 employees across countries and has centers in Pittsburgh, Shanghai, and Hyderabad. It is headquartered in the US and has a market cap of US$17 billion.
